Amavu n'amavuko

Citrate ya Tofacitinib, izwi kandi nka CP-690550 citrate, ni inzitizi ikomeye ya janus kinase 3 (JAK3), hematopoetic selile yagabanijwe na tyrosine kinase igira uruhare mu guhererekanya ibimenyetso bigenga kubaho kwa lymphocyte, gukwirakwizwa, gutandukanya, na apoptose. Kubuzwa ni JAK3 yihariye hamwe no guhitamo inshuro 1000 kurenza iyindi miryango itari JAK. Usibye kubuza JAKS (IC50 = 1 nM), citrate ya tofacitinib inabuza janus kinase 2 (JAK2) na janus kinase 1 (JAK1) hamwe na 20- na 100 munsi yububasha. Nyamara, mu bushakashatsi buherutse gukorwa, guhuza (Ki) bya tofacitinib citrate yerekeza kuri JAK1, JAK2, na JAK3 byavuzwe ko ari 1,6 nM, 21.7 nM, na 6.5 nM.

Reba

Lalitha Vijayakrishnan, R. Venkataramanan na Palak Gulati. Kuvura umuriro hamwe na janus kinase inhibitor CP-690.550. Imigendekere yubumenyi bwa farumasi 2011: 32 (1); 25-34

Ibicuruzwa byatanzwe

• 1. Panagi I, Jennings E, n'abandi. . Microbe yakiriye selile. 2020; 27 (1): 41–53.e6. PMID: 31862381
• 2. McInnes IB, Byers NL, n'abandi. "Kugereranya baricitinib, upadacitinib, na tofacitinib byahujwe no kugenzura amabwiriza ya cytokine mu bimenyetso bya leukocyte." Indwara ya rubagimpande. 2019 Kanama 2; 21 (1): 183. PMID: 31375130
• 3. Liu S, Verma M, n'abandi. . 2018 Mutarama; 141 (1): 257-268.e6. PMID: 28433687
• 4. Zheng, Lufeng, n'abandi. "3 ′ UTR ya pseudogene CYP4Z2P itera ikibyimba angiogenezi muri kanseri y'ibere ikora nka ceRNA ya CYP4Z1." Ubushakashatsi no kuvura kanseri y'ibere (2015): 1-14. PMID: 25701119

Ibisobanuro

Tofacitinib citrate ni umunwa uboneka mu kanwa JAK1 / 2/3 hamwe na IC50s ya 1, 20, na 112 nM. Citrate ya Tofacitinib ifite antibacterial, antifungal na antiviral.

Ububiko

4 ° C, urinde urumuri

* Mubisubizo: -80 ° C, amezi 6; -20 ° C, ukwezi 1 (kurinda urumuri)

Imiterere yimiti

Bifitanye isano na Biologiya

Bifitanye isano na Biologiya

Bifitanye isano na Biologiya

Bifitanye isano na Biologiya

Bifitanye isano na Biologiya